Hints and tips:
Related Special Reports
...Sanofi predicts it could be even bigger, hitting $17bn by 2030....
...Latin America’s largest economy will host vaccine trials for US companies Johnson & Johnson and Novavax, China’s CanSino, Russia’s Gamaleya Institute, Germany’s CureVac, France’s Sanofi Pasteur and Italy...
...Another French effort came to nothing in January when a Covid-19 vaccine out of the Pasteur Institute, which was later licensed to Merck, also failed in clinical trials....
...Angus Thomson, former head of vaccine confidence and coverage at French pharmaceuticals group Sanofi Pasteur, said France’s passport scheme helped jolt “wait-and-see-ers” into action....
...The delay means Sanofi is unlikely to be able to bring a vaccine to market until the end of this year at the earliest....
...He noted it was adding capacity to fill vials with its recent agreement with Sanofi Pasteur....
...Its Sanofi Pasteur vaccine division employs about 10,000 people and has 12 factories globally....
...France’s prestigious Institut Pasteur abandoned its project while Sanofi’s has been delayed. Valneva, a Franco-Austrian biotech, will make its vaccine in Scotland....
...Sanofi’s vaccines division, Sanofi Pasteur, has been collaborating with the Medicines and Healthcare products Regulatory Agency to accelerate the assessment of a new flu inoculation....
...Mortada Othmane, director of the Institut Pasteur in Tangier, said the country was “wise” to rely on the vaccine — and dismissed the concerns in Europe as political....
...Executives from companies including Roche, Sanofi Pasteur and Johnson & Johnson on Thursday said they would share resources and clinical trial data with governments and each other to help increase testing...
...He warned of severe consequences from pushing out a product without thorough preparation, highlighting a dengue fever vaccine developed by Sanofi Pasteur that was given to 1m children in the Philippines...
...IP is not the limiting factor at this stage, says David Loew, executive vice-president at Sanofi Pasteur. “Most vaccines don’t even have IP....
...Dengvaxia, made by Sanofi Pasteur, was being rolled out to more than 800,000 schoolchildren in the Philippines when reports began trickling in of vaccinated children falling seriously ill, and some dying...
...David Loew, executive vice-president of Sanofi Pasteur, the vaccine producer, said a swift commitment totalling “billions” of dollars was needed from governments to underwrite purchases of the most promising...
...Jean Lang, head of R&D global health and partnerships at Sanofi Pasteur, the vaccines division of the French drugs group, said these efforts could prove a game-changer in how to respond rapidly and effectively...
...Mr Cerqueira lives in the country of Louis Pasteur, the French biologist who discovered the principles of vaccination in the 19th century....
...After its manufacturer, Sanofi Pasteur, reported findings that Dengvaxia provides valuable protection for some, but higher risks for others, fears spiralled into a general distrust of the country’s immunisation...
...It emerged on Wednesday that even before Sanofi’s vaccines division, Sanofi Pasteur, had secured a contract from the Philippines government to provide Dengvaxia, it had already imported stocks of its dengue...
...Sanofi Pasteur, the group’s vaccines business division, is the sole influenza vaccine producer in France....
...In 2016, sales at Sanofi Pasteur, the company’s global vaccines business unit, increased 8.8 per cent, to more than €4.5bn and accounted for 13.5 per cent of its €33.8bn total annual sales....
...Olivier Brandicourt, chief executive officer, said in a statement: Sanofi Genzyme, Sanofi Pasteur and emerging markets were once again major contributors to our performance in the quarter....
...Olivier Brandicourt, chief executive, said in a statement: “Sanofi Genzyme, Sanofi Pasteur and emerging markets were once again major contributors to our performance in the quarter....
...Expatriates working at Renault, Interpol and at biotech leaders such as Sanofi-Pasteur are also contributing to population growth....
...Overall sales were driven by the company’s specialty care Sanofi Genzyme (+17.3 per cent in 2016) and Sanofi Pasteur vaccines (+8.8 per cent) units....
International Edition